Asset

Triamcinolone acetonide

Pacira BioSciences Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06977568phase2terminated2025-07-252025-10-16Pacira Pharmaceuticals, IncA Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
NCT06269705phase3active_not_recruiting2024-02-052026-12-01Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis

FDA applications (1)

ApplicationTypeApplicant
NDA 208845NDAPACIRA PHARMACEUTICALS INC

Marketed products (1)

  • ZILRETTA